Cryotherapy as an alternative therapy for the treatment of recalcitrant alopecia areata
Authors
Abstract:
Background: The cold-induced inflammation of cryotherapy mayalter the immunologic processes and structural components ofthe hair follicles responsible for AA. The aim of this study was tostudy the efficacy of cryotherapy in alopecia areata, and totalis.Method: Forty-four patients with recalcitrant scalp alopeciaareata or totalis were treated with cryotherapy. The cryo-systemchosen was a closed contact CO2 system with metallic probes.The patients were evaluated for 4-8 weeks for hair growth.Satisfactory hair growth after 8 weeks was an indication forperforming cryotherapy for the remaining untreated areas.Result: Varying degrees of hair growth were detected in 52.50%of the patients four weeks and in 65.90 % eight weeks aftertreatment. About 38.64% of the patients showed more than 50%hair regrowth 8 weeks after therapy.Conclusion: Cryotherapy is effective for about two-thirds of thepatients with alopecia areata, many of whom are unresponsiveto conventional therapies.
similar resources
Low-Dose Systemic Methotrexate Therapy for Recalcitrant Alopecia Areata
BACKGROUND Alopecia areata (AA) is an autoimmune skin disease difficult to manage and treat. The pathogenesis of AA features a T-cell-associated autoimmune process, and systemic immunosuppressive therapy is prescribed widely for AA. OBJECTIVE To evaluate the efficacy and tolerance of systemic low-dose methotrexate (LD-MTX) therapy in treatment of recalcitrant AA multiplex. METHODS In a retr...
full textLatanoprost for the Treatment of Alopecia Areata of Eyelashes
Background: Latanoprost, a prostaglandin F 2a analogue, is an intraocular pressure lowering drug used in the treatment of glaucoma. Increase in eyelash number, length, pigmentation, curvature is reported after using topical Latanoprost in these patients. The aim of this study was to evaluate the effect of Latanoprost ophthalmic solution on eyelash regrowth in patients with alopecia areata.Metho...
full textSimvastatin/Ezetimibe Therapy for Recalcitrant Alopecia Areata: An Open Prospective Study of 14 Patients
Background Simvastatin belongs to the statin family, whose members have immunomodulatory activities. Ezetimibe have synergetic effects when co-administered with simvastatin. In several case reports, alopecia totalis and alopecia universalis were successfully treated with simvastatin/ezetimibe, suggesting that this combination could be a new efficient therapy for recalcitrant alopecia areata (AA...
full textDPCP for the treatment of alopecia areata.
Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice by many dermatologists. Although there have been no major side effects reported since its initial use, there remain some unknowns regarding its safety. Because DPCP has at least a 40% success rate for cosmetically acceptable regrowth in e...
full textEfficacy of dinitrochlorobenzene in the treatment of alopecia areata
Background: Various kinds of sensitizers are administrated foralopecia areata treatment. The aim of this study was to evaluatetreatment response to Dinitrochlorobenzene (DNCB) in alopeciaareata patients.Method: In this study, 117 patients were treated with DNCBunder a specific checklist. All patients were sensitized with a 2%DNCB and then treated with ascending DNCB concentrations(0.001%-2%). R...
full textTh1 Chemokine CXCL10 and Alopecia Areata: The Possible Target for the Treatment of Alopecia Areata
Alopecia areata (AA) is an organ-specific and cell-mediated autoimmune disease. Recent studies have suggested the most important effector cell of AA is NKG2D+CD8+T cells, and outer root sheath (ORS) cells highly express NKG2D ligands, such as MICA, in AA lesions. T lymphocytes densely surround lesional hair bulbs, which is histologically referred to as “swarm of bees”. Immunohistochemical and r...
full textMy Resources
Journal title
volume 16 issue 2
pages 49- 52
publication date 2013-04-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023